Immunotherapy for nonsmall-cell lung cancer
- 89 Downloads
Systemic chemotherapy for nonsmall-cell lung cancer (NSCLC) has reached a plateau in effectiveness for several years and certainly biological therapy (approved antiangiogenic agents and tyrosine kinase inhibitors) has slightly improved survival; however, the mortality of NSCLC is very high and survival of metastatic disease is less than 2 years. Therefore, new approaches are required to improve current outcomes. Active-specific immunotherapy is an area of oncology that is rapidly expanding and delivering promising results such as asymptomatic prostate cancer with the use of sipuleucel-T. In the field of lung cancer, there are multiple vaccines focused on creating specific antitumor activity in NSCLC. Whole-cell vaccines like belagenpumatucel-L and antigen-specific vaccines like L-BLP25, TG4010, EGF vaccine and MAGE-A3 vaccines are undergoing phase III clinical trials after having demonstrated encouraging results in previous phase II trials with minimum toxicity. Hopefully, positive results will be revealed in the next few years, giving our lung cancer patients a new and more personalized therapy with better quality of life. The short review is indented to give an overview of the current data in the main studies of active immunotherapy for NSCLC.
KeywordsImmunotherapy Nonsmall-cell lung cancer Antigens Vaccines Stimuvax BLP25 MAGE-A3
- 8.Clinicaltrials.gov: Phase III Lucanix vaccine therapy in advanced non-small-cell lung cancer (NSCLC) following front-line chemotherapy (STOP). www.clinicaltrials.gov/ct2/show/NCT00676507. Accessed 1 Feb. 2012.Google Scholar
- 10.Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol. 2007;s25:7554 (Meeting Abstracts).Google Scholar
- 11.Clinicaltrials.gov: GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small-cell lung cancer.http:\\www.clinicaltrials.gov/ct2/show/NCT00480025. Accessed 1 Feb. 2012.
- 16.Clinicaltrials.gov: Cancer vaccine study for unresectable stage III non-small-cell lung cancer.http:\\www.clinicaltrials.gov/ct2/show/NCT00409188. Accessed 1 Feb 2012.
- 19.Acres B, Quoix E, Ramlau R, et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J Clin Oncol. 2009;s27:3027 (Meeting Abstracts).Google Scholar
- 20.Clinicaltrials.gov: Immunotherapy with TG4010 in patients with advanced non-small-cell lung cancerhttp://clinicaltrials.gov/ct2/show/NCT01383148. Accessed 1 Feb 2012.
- 21.Rodriguez G, Albisa A, Viña L, et al. Manufacturing process development for an epidermal growth factor-based cancer vaccine. Int Biopharm. 2008;21(10):36–42.Google Scholar
- 23.Garcia B, Neninger E, de la Torre A, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res. 2008;14(3):840–6.CrossRefPubMedGoogle Scholar